COMPANY RESEARCHPharmaron offers Biologics characterization, PK/TK, immunogenicity and biomarkers. This is the analytical service business of an integrated CRO/CDMO.
Bond principal, not equity financing or net proceeds; due in 2027.
Profile review: 2026-11-06 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
| Period | Currency / basis | Revenue | Net profit | Operating cash flow | Report |
|---|---|---|---|---|---|
| FY2025 2025-12-31 | CNY PRC Accounting Standards / consolidated | 14,095,078,734.95 | 1,663,898,879.44 Net income attributable to shareholders of the listed company | 3,221,047,215.59 | Original ↗ |
| 2026Q3 (YTD) 2026-09-30 | CNY PRC Accounting Standards / consolidated | 12,003,359,881.83 | 1,247,121,391.66 Net income attributable to shareholders of the listed company | 1,906,783,000.05 | Original ↗ |
Disease tags match recorded text mentions and require program-level verification.
Provides cyclic and other complex peptide synthesis, noncanonical amino-acid modifications, peptide libraries, and in vitro oral-bioavailability screening. It is included as a discovery and development service provider.
The company explicitly supports PROTACs, hydrophobic tags, and molecular glues through FFS, FTE, and integrated discovery models, including target engagement, ubiquitination, proteasome dependence, and bioanalysis.
Offers tablet, capsule, solution, and suspension development from early FIH/POC studies to market formulations, including spray drying, immediate-release, modified-release, and pediatric formulations.
The materials science page explicitly lists polymorph, salt, and cocrystal screening for solid-form selection.
Biologics characterization, PK/TK, immunogenicity and biomarkers
Integrated CRO/CDMO analytical services
The Baltimore CPC lists FIH, carbon-14 human ADME, TQT and DDI, offered as standalone or integrated studies.
An integrated platform combining laboratory services, CMC and small-molecule CDMO, clinical research, and biologics/cell and gene therapy services.
Listed as SZSE 300759 / HKEX 03759; original 2025 annual and 2026Q3 (YTD) reports reviewed.
China clinical platform within a global development network, with operations linked to SMO and recruitment teams. Distinguish China delivery from the group’s US and UK early-phase facilities.
International delivery scope: China-based / China-origin platform
IIT evidence: IIT capability not established by reviewed sources
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Cyclic peptide synthesis and oral absorption assessment | Client-dependent · Client-dependent | 未披露 | Client results not disclosed |
| Chemistry and biology through DMPK, IND support, and GMP | Program-dependent / not disclosed · Determined by the collaboration program | Platform / services | This record does not claim platform-wide human validation |
| Formulation development / contract manufacturing capabilities | Defined by the client project · Defined by the client project | Services / platform | Service pages do not establish human evidence for every project |
| Solid-state R&D capabilities | Determined by the submitted sample and research question · Not applicable; service capability | Services / platform | Not applicable; not a human clinical program |
| FIH / early-phase clinical research | Baltimore, Maryland CPC; not a group-wide site claim · Not applicable; population depends on protocol | Services / platform | Clinical research service, not the company’s therapeutic product |
| 14C-hADME / TQT / DDI | Lists standalone or integrated studies; protocol and site qualification require verification · Not applicable; population depends on protocol | Services / platform | Clinical research service, not the company’s therapeutic product |
| Integrated laboratory, CMC, and clinical research services | Not applicable (services/platform) · Drug research and manufacturing services for clients | Services / platform | Not applicable: service capabilities are not clinical drug candidates; E4 does not rate service quality. |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Pharmaron reported consolidated revenue of RMB12.003 billion, up 19.01%, and attributable net income of RMB1,247.1 million for the nine months ended September 30, 2026. CDMO revenue rose 31.72%, while new CDMO orders increased more than 40%. The quarterly filing is unaudited and covers the year-to-date period.
Johnson & Johnson reported that 58% of patients receiving icotrokinra 200 mg achieved ACR20 at Week 16 in ICONIC-PsA 1, versus 41% with placebo. The oral IL-23 receptor peptide also showed skin responses. The company reported no new safety signals through Week 24; active psoriatic arthritis remains an investigational indication.
Entera reported $265.9 million in cash and cash equivalents at September 30, plus $6.5 million in restricted cash. Its November 6 update targets first site activation for an approximately 900-patient EB613 osteoporosis Phase 3 trial in late 2026. EB613 is an oral PTH(1-34) program, included here as an adjacent oral-peptide delivery development, not a cyclic-peptide candidate.
Johnson & Johnson reported that ICONIC-ASCEND met its Week 16 co-primary endpoints: PASI 90 responses were 55.2% with icotrokinra versus 3.6% with placebo, and IGA 0/1 responses were 70.4% versus 9.5%. At Week 28, the oral peptide met noninferiority criteria versus ustekinumab across multiplicity-controlled key secondary skin-clearance endpoints.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.